论文部分内容阅读
目的观察依达拉奉治疗急性脑梗死的疗效和安全性。方法将90例急性脑梗死患者随机分为治疗组(44例)和对照组(46例)。对照组予以抗血小板聚集,活血化瘀,予脑细胞活化剂及对症治疗。治疗组在对照组综合治疗的基础上加依达拉奉。结果治疗后两组评分均有改善,但治疗组改善更明显,与对照组比较差异有显著性(P<0.05)。结论依达拉奉治疗急性脑梗死能更有效的改善神经功能,安全性高。
Objective To observe the efficacy and safety of edaravone in the treatment of acute cerebral infarction. Methods Ninety patients with acute cerebral infarction were randomly divided into treatment group (44 cases) and control group (46 cases). The control group was given anti-platelet aggregation, blood circulation, to brain cell activators and symptomatic treatment. The treatment group in the control group based on comprehensive treatment plus edaravone. Results After treatment, the scores of both groups were improved, but the improvement of the treatment group was more obvious. The difference was significant compared with the control group (P <0.05). Conclusion Edaravone can improve neurological function more effectively and safely in acute cerebral infarction.